Clinical Trial Update: Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update investigating atezolizumab with carboplatin, paclitaxel, and bevacizumab in NSCLC patients with EGFR mutations or ALK translocat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Samsung Medical Center | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: UNKNOWN